HC Wainwright & Co. Maintains Buy on SAB Biotherapeutics, Raises Price Target to $10
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Emily Bodnar maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and raises the price target from $7 to $10.
HC Wainwright & Co. analyst Emily Bodnar maintains SAB Biotherapeutics (NASDAQ:SABS) with a Buy and raises the price target from $7 to $10.